The Shuman Law Firm Investigates BioScrip, Inc.
28 Janvier 2015 - 2:00AM
Business Wire
The Shuman Law Firm announces that it is investigating potential
claims against certain officers and directors of BioScrip, Inc.
(“BioScrip” or the “Company”) (Nasdaq: BIOS). BioScrip is a New
York-based company that provides home infusion and other home care
services, and pharmacy benefit management services in the United
States.
The Firm’s investigation relates to a U.S. Department of Justice
Press Release which disclosed that BioScrip has agreed to forfeit
$15 million for the Company’s participation in a kickback scheme
with Novartis Pharmaceuticals, Inc.
If you currently own BioScrip common stock and are interested in
discussing your rights, or have information relating to this
investigation, please contact Kip B. Shuman or Rusty E. Glenn
toll-free at 866-569-4531 or email Mr. Shuman at
kip@shumanlawfirm.com or email Mr. Glenn at
rusty@shumanlawfirm.com.
The Shuman Law Firm represents investors throughout the nation,
concentrating its practice in stockholder litigation.
The Shuman Law FirmKip B. Shuman, Esq., 866-569-4531 or
303-861-3003kip@shumanlawfirm.comRusty E. Glenn, Esq., 866-569-4531
or 303-861-3003rusty@shumanlawfirm.comFax:
303-536-7849www.shumanlawfirm.com
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024